Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.

Structure-activity relationships around a novel series of B-Raf(V600E) inhibitors are reported. The enzymatic and cellular potencies of inhibitors derived from two related hinge-binding groups were compared and3-methoxypyrazolopyridine proved to be superior. The 3-alkoxy group of lead B-Raf(V600E) inhibitor 1 was extended and minimally affected potency. The propyl sulfonamide tail of compound 1, which occupies the small lipophilic pocket formed by an outward shift of the αC-helix, was expanded to a series of arylsulfonamides. X-ray crystallography revealed that this lipophilic pocket unexpectedly enlarges to accommodate the bulkier aryl group.

[1]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[2]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[3]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[4]  Baoguang Zhao,et al.  Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[5]  Ramona N Plant,et al.  Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. , 2010, Bioorganic & medicinal chemistry letters.

[6]  J. Fargnoli,et al.  Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[7]  M. A. García-Cabezas,et al.  The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. , 2006, Endocrine-related cancer.

[8]  Tyler Risom,et al.  Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors. , 2011, ACS medicinal chemistry letters.

[9]  N. Sharif,et al.  2,3-Diaminopyrazines as Rho kinase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[10]  Tyler T. Risom,et al.  Discovery of pyrrolopyrimidine inhibitors of Akt. , 2010, Bioorganic & medicinal chemistry letters.

[11]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[12]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[13]  N. Gray,et al.  Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. , 2010, Bioorganic & medicinal chemistry letters.

[14]  J. Becker,et al.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.

[15]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[16]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[17]  P. Bamborough,et al.  4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[18]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.